Endocrinology and Metabolism

Review Article

Bone Metabolism
Emerging Therapies for Osteoporosis: Michael R. McClung; Endocrinol Metab. 2015;30(4):429-435. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.429

4,424 View
47 Download
23 Web of Science
21 Crossref

Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity like teriparatide. Recent data from the phase 3 fracture prevention trial demonstrate that this agent is effective in reducing fracture risk. Inhibiting cathepsin K reduces bone resorption without decreasing the numbers or activity of osteoclasts, thereby preserving or promoting osteoblast function. Progressive increases in bone mineral density (BMD) have been observed over 5 years. Early data suggest that odanacatib effectively reduces fracture risk. Lastly, inhibiting sclerostin with humanized antibodies promotes rapid, substantial but transient increases in bone formation while inhibiting bone resorption. Marked increases in BMD have been observed in phase 2 studies. Fracture prevention studies are underway. The new therapies with novel and unique mechanisms of action may, alone or in combination, provide more effective treatment options for our patients.

Citations

Citations to this article as recorded by

The osteocyte as a signaling cell
Jesus Delgado-Calle, Teresita Bellido
Physiological Reviews.2022; 102(1): 379. CrossRef
Combining sclerostin neutralization with tissue engineering: An improved strategy for craniofacial bone repair
Sophie Maillard, Ludovic Sicard, Caroline Andrique, Coralie Torrens, Julie Lesieur, Brigitte Baroukh, Thibaud Coradin, Anne Poliard, Lotfi Slimani, Catherine Chaussain
Acta Biomaterialia.2022; 140: 178. CrossRef
Effects of sclerostin antibody on bone healing
Atsushi Mihara, Kiminori Yukata, Toshihiro Seki, Ryuta Iwanaga, Norihiro Nishida, Kenzo Fujii, Yuji Nagao, Takashi Sakai
World Journal of Orthopedics.2021; 12(9): 651. CrossRef
Combining Sclerostin Neutralization with Tissue Engineering: An Improved Strategy for Craniofacial Bone Repair
Sophie Maillard, Ludovic Sicard, Caroline Andrique, Coralie Torrens, Julie Lesieur, Brigitte Baroukh, Thibaud Coradin, Anne Poliard, Lotfi Slimani, Catherine Chaussain
SSRN Electronic Journal.2021;[Epub] CrossRef
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
Endocrinology and Metabolism.2020; 35(1): 55. CrossRef
Clinical Application of Teriparatide in Fracture Prevention
Yuehong Chen, Ronghan Liu, Aubryanna Hettinghouse, Shuya Wang, Gang Liu, Chuan-ju Liu
JBJS Reviews.2019; 7(1): e10. CrossRef
The Emerging Role of Osteocytes in Cancer in Bone
Emily G Atkinson, Jesús Delgado‐Calle
JBMR Plus.2019;[Epub] CrossRef
Osteoporosis therapies might lead to intervertebral disc degeneration via affecting cartilage endplate
Zhen Sun, Zhuo-Jing Luo
Medical Hypotheses.2019; 125: 5. CrossRef
Polymersome nanoparticles for delivery of Wnt-activating small molecules
Edoardo Scarpa, Agnieszka A Janeczek, Alethia Hailes, Maria C de Andrés, Antonio De Grazia, Richard OC Oreffo, Tracey A Newman, Nicholas D Evans
Nanomedicine: Nanotechnology, Biology and Medicine.2018; 14(4): 1267. CrossRef
Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects
Jing Wu, Qi Shen, Wei Cui, Yu Zhao, Yue Huai, Yu-chao Zhang, Bei-hua Bao, Chen-xi Liu, Qing Jiang, Jian-xin Li
Acta Pharmacologica Sinica.2018; 39(2): 230. CrossRef
Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
Chee Kian Chew, Bart L. Clarke
Maturitas.2017; 97: 53. CrossRef
Dried and free flowing granules of Spinacia oleracea accelerate bone regeneration and alleviate postmenopausal osteoporosis
Sulekha Adhikary, Dharmendra Choudhary, Naseer Ahmad, Sudhir Kumar, Kapil Dev, Naresh Mittapelly, Gitu Pandey, Prabhat Ranjan Mishra, Rakesh Maurya, Ritu Trivedi
Menopause.2017; 24(6): 686. CrossRef
Romosozumab for the treatment of osteoporosis
Leonardo Bandeira, E. Michael Lewiecki, John P. Bilezikian
Expert Opinion on Biological Therapy.2017; 17(2): 255. CrossRef
The quest for new drugs to prevent osteoporosis-related fractures
T. J. de Villiers
Climacteric.2017; 20(2): 103. CrossRef
Role and mechanism of action of sclerostin in bone
Jesus Delgado-Calle, Amy Y. Sato, Teresita Bellido
Bone.2017; 96: 29. CrossRef
Biochemical Testing Relevant to Bone
Chee Kian Chew, Bart L. Clarke
Endocrinology and Metabolism Clinics of North America.2017; 46(3): 649. CrossRef
Re-Invigorating the Osteoporosis Message
Michael R. McClung
Endocrine Practice.2016; 22(9): 1130. CrossRef
Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis
Leonardo Bandeira, E. Michael Lewiecki, John P. Bilezikian
Expert Opinion on Drug Metabolism & Toxicology.2016; 12(6): 681. CrossRef
Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
Michael Pazianas, Bo Abrahamsen
Annals of the New York Academy of Sciences.2016; 1376(1): 5. CrossRef
Anti-senescence and Anti-inflammatory Effects of the C-terminal Moiety of PTHrP Peptides in OA Osteoblasts
Julia Platas, Maria Isabel Guillén, Francisco Gomar, Miguel Angel Castejón, Pedro Esbrit, Maria José Alcaraz
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.2016; : glw100. CrossRef
Osteocytic signalling pathways as therapeutic targets for bone fragility
Lilian I. Plotkin, Teresita Bellido
Nature Reviews Endocrinology.2016; 12(10): 593. CrossRef

Original Article

The Effects of Combination Therapy of Cathepsin K Inhibitor and PTH on Change in Bone Mineral Density in an Animal Model of Osteoporosis.: Seung Hun Lee, Jung Min Koh, Young Sun Lee, Beom Jun Kim, Je Yong Choi, Ghi Su Kim; Endocrinol Metab. 2011;26(4):303-309. Published online December 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.4.303

2,106 View
27 Download
1 Crossref

Abstract PDF

BACKGROUND
We hypothesized that combination therapy of cathepsin K inhibitor (CTKi) and human parathyroid hormone (1-34) (teriparatide, PTH) would overcome the coupling phenomenon of bone resorption and formation and thus may rapidly increase bone mass. METHODS: We selected a dose of zoledronic acid (ZA) that had shown similar effects with CTKi on body bone mineral density (BMD) change during the preliminary experiment. Female mice were subjected to ovariectomized (OVX control) or a sham operation (SHAM group). The mice were treated with CTKi (CTKi group), ZA (ZA group), PTH (PTH group) or with a combination of PTH with ZA (ZA + PTH group) or CTKi (CTKi + PTH group) for 8 weeks. Total BMD was measured before the operation and at 4 and 8 weeks. RESULTS: In the preliminary results, 10 microg/kg of ZA showed similar BMD changes with CTKi. Compared with the OVX control, BMD in the SHAM, ZA, CTKi, PTH, ZA + PTH, and CTKi + PTH groups was significantly increased after treatment. BMD in the CTKi + PTH group, but not in the ZA + PTH group increased more significantly than in the PTH group at the end of treatment. Compared with the OVX control, changes in BMD in the SHAM, ZA, CTKi, PTH, ZA + PTH, and CTKi + PTH groups increased significantly after 8 weeks of treatment. The change in BMD in the CTKi + PTH group, but not in the ZA + PTH group was more significantly increased than the change in BMD in the PTH group. CONCLUSION: When combined with PTH, CTKi augmented the anabolic action of PTH. Therefore, combination therapy with CTKi and PTH might be a new therapeutic modality capable of overcoming the coupling phenomenon, thereby markedly and rapidly increasing bone mass.

Citations

Citations to this article as recorded by

The Effects of Combination Therapy of Cathepsin K Inhibitor and PTH on Change of Bone Mineral Density in Animal Model of Osteoporosis
Yumie Rhee
Endocrinology and Metabolism.2011; 26(4): 295. CrossRef

First
Prev
Page of 1
Next
Last

Search